Clinical Trial Update: Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib as subsequent therapy after an immune checkpoint-based treatment in renal cell carcinoma is underway, with status not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Renal Cell Cancer | Phase 2 | Status: UNKNOWN